Skip to main content

Philips and Mass General Brigham announce collaboration to improve patient care with live AI-powered insights

Physician caring for patient

Nurse caring for patient

System Architecture

February 21, 2025

Integrating advanced data analytics into clinical practice to improve patient care

Amsterdam, The Netherlands and Cambridge, MA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Mass General Brigham (MGB), home to one of the largest hospital system-based research enterprises in the US, today announced a new collaboration to develop and deploy advanced data infrastructure and AI designed to integrate and process live healthcare data from a wide range of sources to improve patient care.

Today, healthcare providers often rely on disparate data sources, including static Electronic Medical Record (EMR) data, clinical notes, and isolated device alarms. By streaming accurate, reliable and detailed data from medical devices and other sources, Philips and MGB aim to create a scalable, unified, near real-time data and insights ecosystem. Powered by Philips software platforms, the collaboration aims to enable clinicians to capture, analyze, and react to data as it is available, potentially improving the effectiveness and efficiency of patient care.

“This exciting collaboration marks a key step forward in healthcare innovation, harnessing the full potential of AI and medical device data to advance patient safety, operational efficiency, clinician ergonomics, while opening new discovery possibilities,” said Dr. Tom McCoy, Medical Director of Biomedical Engineering at Massachusetts General Hospital. “By mobilizing previously siloed medical device data into an integrated high speed, high resiliency, real time data fabric we will be able to deliver the transformative potential of software to the patients who need it most.”

The collaboration will leverage a combination of Philips technologies to unify active data streaming from medical devices at the bedside, such as ventilators and monitors, with other longitudinal clinical data, such as lab results and EMR data, to create a comprehensive and actionable data environment. Philips Capsule Medical Device Information Platform brings together data from different devices, allowing Philips Clinical Insights Manager to facilitate retrospective analysis and testing, and Philips Capsule Surveillance to leverage continuous algorithmic processing to deliver smart alerts into live clinical practice.

For the collaboration, Mass General Brigham is bringing together the expertise of its biomedical engineering team, clinical sub-specialists, digital teams and internal AI business unit (Mass General Brigham AI) with Philips’ research and business teams. The joint effort will deliver data insights, enhance data integration and foster the development of new algorithms, capable of identifying patient-cohort patterns and generating smart alerts for clinical intervention. These alerts will provide clinicians with actionable insights at critical moments to support better patient care.

An initial research program as part of the collaboration focuses on patients undergoing continuous, real-time heart monitoring. By analyzing this data, the research aims to improve early detection of cardiac events and other critical health issues, potentially saving lives and expediting treatment.

“This collaboration between Philips and Mass General Brigham represents a significant step forward in the integration of advanced data analytics into clinical practice,” said Betsabeh Madani Hermann, Global Head of Research at Philips. “By developing predictive data analytics and AI algorithms, key tools for enhancing patient care, we’re empowering clinicians and supporting better care for more people.”

For further information, please contact:

Anna Hogrebe
Philips Global External Relations
Tel.: +1 416 270 6757
E-Mail: anna.hogrebe@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.